glycopyrronium Topical Wipes

DRUG3 trials

Sponsors

Journey Medical Corporation

Conditions

Hyperhidrosis

Phase 3

Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

CompletedNCT02530294

Journey Medical CorporationHyperhidrosis

Start: 2015-08-31End: 2016-04-30Updated: 2021-08-25

Study of Glycopyrronium in Axillary Hyperhydrosis

CompletedNCT02530281

Journey Medical CorporationHyperhidrosis

Start: 2015-07-31End: 2016-03-31Updated: 2021-08-25

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

CompletedNCT02553798

Journey Medical CorporationHyperhidrosis

Start: 2015-08-31End: 2016-12-31Updated: 2021-08-25

Related Papers

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.

2021-01-1210 citations

Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study

Pediatric Dermatology2020-03-0820 citations

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.

2019-08-0120 citations

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.

2019-02-0122 citations

Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.

2018-11-1916 citations